ECOG-ACRIN (E4805) Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Aflibercept is a recombinantly-produced fusion protein that has potent anti-VEGF activity. We tested whether aflibercept has clinical activity in clear cell renal cell carcinoma (ccRCC). The recommended Phase 2 dose was 4 mg/kg but several patients treated at 1 mg/kg demonstrated prolong...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Genitourin Cancer
Hlavní autoři: Pili, Roberto, Jegede, Opeyemi, Carducci, Michael A., Manola, Judith, Groteluschen, David L., Appleman, Leonard L., Liu, Glenn, Shanks, James C., Dakhil, Shaker R., Dutcher, Janice, DiPaola, Robert S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675826/
https://ncbi.nlm.nih.gov/pubmed/28545998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.04.023
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky